IDEAYA Biosciences, Inc.
US ˙ NasdaqGS ˙ US45166A1025

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark Lackner. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark Lackner has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ZNTL / Zentalis Pharmaceuticals, Inc. Chief Scientific Officer 512,856
US:IDYA / IDEAYA Biosciences, Inc. SVP, Head of Biology 45,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark Lackner. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IDYA / IDEAYA Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IDYA / IDEAYA Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDYA / IDEAYA Biosciences, Inc. Insider Trades
Insider Sales IDYA / IDEAYA Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IDYA / IDEAYA Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDYA / IDEAYA Biosciences, Inc. Insider Trades
Insider Purchases ZNTL / Zentalis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IDYA / IDEAYA Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZNTL / Zentalis Pharmaceuticals, Inc. Insider Trades
Insider Sales ZNTL / Zentalis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IDYA / IDEAYA Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-02-03 ZNTL Lackner Mark 14,368 1.7115 14,368 1.7115 24,591 64 1.0400 -9,647 -39.23
2025-01-02 ZNTL Lackner Mark 4,411 3.1200 4,411 3.1200 13,762
2024-02-02 ZNTL Lackner Mark 1,585 11.5400 1,585 11.5400 18,291

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZNTL / Zentalis Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark Lackner as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-02-05 2025-02-03 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
S - Sale -14,368 512,856 -2.73 1.71 -24,591 877,753
2025-02-05 2025-02-03 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
A - Award 335,907 527,224 175.58
2025-01-03 2025-01-02 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
S - Sale -4,411 191,317 -2.25 3.12 -13,762 596,909
2024-02-05 2024-02-02 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,585 195,728 -0.80 11.54 -18,291 2,258,701
2024-02-05 2024-02-01 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
A - Award 141,000 197,313 250.39
2024-01-03 3 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
16,313
2024-01-03 2024-01-02 4 ZNTL Zentalis Pharmaceuticals, Inc.
Common Stock
A - Award 40,000 56,313 245.20
2021-02-26 2021-02-24 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
A - Award 45,000 45,000
2021-02-10 2021-02-10 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -596 33,014 -1.77
2021-02-10 2021-02-10 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -596 0 -100.00 21.00 -12,516
2021-02-10 2021-02-10 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 596 596 6.98 4,160 4,160
2021-02-10 2021-02-09 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -1,104 33,610 -3.18
2021-02-10 2021-02-09 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -1,104 0 -100.00 21.05 -23,234
2021-02-10 2021-02-09 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 1,104 1,104 6.98 7,706 7,706
2021-02-10 2021-02-08 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -300 34,714 -0.86
2021-02-10 2021-02-08 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -200 0 -100.00 21.00 -4,200
2021-02-10 2021-02-08 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -100 200 -33.33 21.02 -2,102 4,204
2021-02-10 2021-02-08 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 300 300 6.98 2,094 2,094
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -1,123 35,014 -3.11
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -377 61,760 -0.61
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -800 0 -100.00 18.79 -15,034
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -1,701 800 -68.01 18.30 -31,124 14,638
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 1,123 2,501 81.49 6.98 7,839 17,457
2021-01-28 2021-01-26 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 377 1,378 37.66 4.62 1,742 6,366
2020-06-18 2020-06-17 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -373 62,137 -0.60
2020-06-18 2020-06-17 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -373 0 -100.00 19.91 -7,428
2020-06-18 2020-06-17 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 373 373 4.62 1,723 1,723
2020-06-18 2020-06-16 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -2,863 36,137 -7.34
2020-06-18 2020-06-16 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
M - Exercise -3,887 62,510 -5.85
2020-06-18 2020-06-16 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -6,750 0 -100.00 14.93 -100,761
2020-06-18 2020-06-16 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 2,863 6,750 73.66 6.98 19,984 47,115
2020-06-18 2020-06-16 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
M - Exercise 3,887 3,887 4.62 17,958 17,958
2020-06-04 2020-06-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -104 0 -100.00 10.11 -1,051
2020-06-04 2020-06-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -333 104 -76.20 9.73 -3,241 1,012
2020-06-04 2020-06-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock
S - Sale X -408 437 -48.28 8.55 -3,487 3,735
2020-02-25 2020-02-21 4 IDYA IDEAYA Biosciences, Inc.
Stock Option (right to buy)
A - Award 40,000 40,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)